A gene expression promoter for skin beautification contains a fermented extract of aspergillus oryzae as an effective component. The gene expression promotor for skin beautification causes expression of at least one gene for skin beautification among BMP-2, TGFB1, CLDN7, HB-EGF, VEGF-A, LCE3D, and PPAR-D. The fermented extract of aspergillus oryzae is extracted using water after steamed rice as a raw material is fermented with aspergillus oryzae.

A gene expression promoter for skin beautification contains a fermented extract of aspergillus oryzae as an effective component. The gene expression promotor for skin beautification causes expression of at least one gene for skin beautification among BMP-2, TGFB1, CLDN7, HB-EGF, VEGF-A, LCE3D, and PPAR-D. The fermented extract of aspergillus oryzae is extracted using water after steamed rice as a raw material is fermented with aspergillus oryzae.

The present invention is directed to a method for differentiating between ASD phenotype 1, phenotype 2 and other ASD patients, wherein the method comprises: administering an Nrf2-activator to a subject, and identifying the subject as an ASD phenotype 1 patient if the subject shows a negative response, as a phenotype 2 patient if he shows a positive response and as another ASD patient if he does not show a positive nor a negative response, wherein the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD. Likewise, the present invention is directed to an Nrf2-activator for use in differentiating between autism spectrum disorder (ASD) phenotype 1 patients, phenotype 2 patients and other ASD patients, wherein the Nrf2-activator is administered to a subject, wherein a phenotype 1 patient is identified by a negative response, a phenotype 2 patient is identified by a positive response and other ASD patients are identified by the absence of a positive and a negative wherein the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD.

The present invention is directed to a method for differentiating between ASD phenotype 1, phenotype 2 and other ASD patients, wherein the method comprises: administering an Nrf2-activator to a subject, and identifying the subject as an ASD phenotype 1 patient if the subject shows a negative response, as a phenotype 2 patient if he shows a positive response and as another ASD patient if he does not show a positive nor a negative response, wherein the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD. Likewise, the present invention is directed to an Nrf2-activator for use in differentiating between autism spectrum disorder (ASD) phenotype 1 patients, phenotype 2 patients and other ASD patients, wherein the Nrf2-activator is administered to a subject, wherein a phenotype 1 patient is identified by a negative response, a phenotype 2 patient is identified by a positive response and other ASD patients are identified by the absence of a positive and a negative wherein the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD.

The present invention relates to a composition comprising a mixed alcoholic extract of eighteen botanical ingredients formulated into capsules for the treatment of H1N1 flu, strep, pneumonia, and Covid-19.

The present invention relates to a composition comprising a mixed alcoholic extract of eighteen botanical ingredients formulated into capsules for the treatment of H1N1 flu, strep, pneumonia, and Covid-19.

The present invention relates to a composition comprising a mixed alcoholic extract of eighteen botanical ingredients formulated into capsules for the treatment of H1N1 flu, strep, pneumonia, and Covid-19.

A composition useful for treating immune-mediated inflammatory diseases or cancer in mammalian subjects is disclosed. The composition comprises a synergistic combination of a cannabis derived compound, and a medicinal mushroom.

A composition useful for treating immune-mediated inflammatory diseases or cancer in mammalian subjects is disclosed. The composition comprises a synergistic combination of a cannabis derived compound, and a medicinal mushroom.

The invention relates to an anti-hypercholesterolemia composition and a method of manufacturing the composition. Accordingly, the present invention discloses the composition to lower the cholesterol formation and a method of manufacturing the same. The anti-hypercholesterolemia composition comprises Basella alba leaf extract in the range of 30 to 70 wt %, red yeast rice extract in the range of 5 to 50 wt %, squalene extract in the range of 1 to 30 wt %, Cordyceps extract in the range of 10 to 70 wt % and at least one nutraceutically or pharmaceutically acceptable excipient in the range of 0.01 to 50 wt %.